Inhibiting MAT2A and reducing SAM levels has been proposed to cause PRMT5 inhibition both by removing its substrate and, in the case of MTAP-negative tumours, by providing a greater opportunity for MTA binding. Here, PRMT5 is linked to neoplasm.